Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Galera Therapeutics Galera Reports First Quarter 2024 Financial Results and Recent Corporate Updates May 13, 2024 From Galera Therapeutics Via GlobeNewswire Tickers GRTX Galera Adopts Limited Duration Stockholder Rights Agreement May 03, 2024 From Galera Therapeutics Via GlobeNewswire Tickers GRTX Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates March 28, 2024 From Galera Therapeutics Via GlobeNewswire Tickers GRTX Galera Reports Third Quarter 2023 Financial Results and Recent Corporate Updates November 14, 2023 From Galera Therapeutics Via GlobeNewswire Tickers GRTX Galera Announces Receipt of Type A Meeting Minutes and Strategic Update October 31, 2023 From Galera Therapeutics Via GlobeNewswire Tickers GRTX Galera Schedules Type A Meeting with FDA to Discuss Next Steps for Avasopasem September 18, 2023 From Galera Therapeutics Via GlobeNewswire Tickers GRTX Galera to Participate in the H.C. Wainwright 25th Annual Global Investment Conference September 05, 2023 From Galera Therapeutics Via GlobeNewswire Tickers GRTX Galera Reports Second Quarter 2023 Financial Results and Recent Corporate Updates August 14, 2023 From Galera Therapeutics Via GlobeNewswire Tickers GRTX Galera Receives Complete Response Letter from U.S. FDA for Avasopasem Manganese August 09, 2023 From Galera Therapeutics Via GlobeNewswire Tickers GRTX Galera Presents Additional Chronic Kidney Disease Data from ROMAN Trial at 2023 ASCO Annual Meeting June 05, 2023 From Galera Therapeutics Via GlobeNewswire Tickers GRTX Galera Announces FDA Orphan Drug Designation Granted to Rucosopasem for Pancreatic Cancer May 18, 2023 From Galera Therapeutics Via GlobeNewswire Tickers GRTX Galera Reports First Quarter 2023 Financial Results and Recent Corporate Updates May 11, 2023 From Galera Therapeutics Via GlobeNewswire Tickers GRTX Galera Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 04, 2023 From Galera Therapeutics Via GlobeNewswire Tickers GRTX Galera Expands Commercial Leadership Team May 01, 2023 From Galera Therapeutics Via GlobeNewswire Tickers GRTX Galera to Present One-Year Reductions in Cisplatin-Related Chronic Kidney Disease Data from ROMAN Trial at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting April 26, 2023 From Galera Therapeutics Via GlobeNewswire Tickers GRTX Galera Announces Presentation of Supplemental Analysis of Phase 3 ROMAN Trial at European Congress on Head and Neck Oncology March 10, 2023 From Galera Therapeutics Via GlobeNewswire Tickers GRTX Galera Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Updates March 08, 2023 From Galera Therapeutics Via GlobeNewswire Tickers GRTX Galera Therapeutics Announces Pricing of Registered Direct Offering of $30 Million of Common Stock and Warrants February 15, 2023 From Galera Therapeutics Via GlobeNewswire Tickers GRTX Galera Announces FDA Acceptance and Priority Review of Avasopasem NDA for Radiotherapy-Induced Severe Oral Mucositis February 15, 2023 From Galera Therapeutics Via GlobeNewswire Tickers GRTX Galera Submits New Drug Application for Avasopasem for Severe Oral Mucositis December 12, 2022 From Galera Therapeutics Via GlobeNewswire Tickers GRTX Galera to Present at Piper Sandler Annual Healthcare Conference November 22, 2022 From Galera Therapeutics Via GlobeNewswire Tickers GRTX Galera Reports Third Quarter 2022 Financial Results and Recent Corporate Updates November 09, 2022 From Galera Therapeutics Via GlobeNewswire Tickers GRTX Galera Announces Presentation of Phase 3 ROMAN Long-term Follow-up Data at 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting October 26, 2022 From Galera Therapeutics Via GlobeNewswire Tickers GRTX Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.